Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway

Fineline Cube Feb 11, 2026
Company Drug

Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections

Fineline Cube Feb 11, 2026
Company Drug

Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China

Fineline Cube Feb 11, 2026
Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Company Drug

Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...

Company Deals

Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis

Fineline Cube Nov 16, 2022

Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...

Company Deals

Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round

Fineline Cube Nov 16, 2022

China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...

Company Drug

Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa

Fineline Cube Nov 15, 2022

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...

Company Deals

Silk Round Fund and INA Invest in Indonesian Pharma Companies

Fineline Cube Nov 15, 2022

The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...

Company Drug

LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study

Fineline Cube Nov 15, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China

Fineline Cube Nov 15, 2022

China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...

Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Company Drug

Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216

Fineline Cube Nov 15, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...

Company Drug

Yabao Receives FDA Clearance for Generic Nexavar

Fineline Cube Nov 15, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...

Company Deals

Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China

Fineline Cube Nov 15, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...

Company Deals

Sansure Biotech Partners with UBC to Manufacture in Indonesia

Fineline Cube Nov 15, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...

Company

HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals

Fineline Cube Nov 15, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...

Company Deals

Harbour BioMed and WuXi Biologics Announce Strategic Collaboration

Fineline Cube Nov 15, 2022

Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...

Company Drug

Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...

Policy / Regulatory

CDE Issues Guidelines for Bispecific Antibody Antitumor Drug Development

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company Drug

AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval

Fineline Cube Nov 14, 2022

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...

Posts pagination

1 … 557 558 559 … 623

Recent updates

  • China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway
  • AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge
  • Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%
  • Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections
  • Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NHSA Launches Reference Drug Pre-Communication System to Streamline Reimbursement Pathway

Company

AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge

Company

Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%

Company Drug

Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.